Translational implications for off-the-shelf immune cells expressing chimeric antigen receptors

Molecular Therapy

Volumn 24, Issue 7, 2016, Pages 1178-1186

  Torikai, Hiroki ^a   Cooper, Laurence J N ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b Ziopharm Oncology Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; T LYMPHOCYTE RECEPTOR; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ALLOIMMUNITY; CELLULAR DISTRIBUTION; CRYOPRESERVATION; EFFECTOR CELL; GAMMA DELTA T LYMPHOCYTE; GENETIC ENGINEERING; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOMODULATION; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; T CELL DEPLETION; ADVERSE EFFECTS; ANIMAL; BIOLOGICAL THERAPY; GENE EXPRESSION; GENE THERAPY; GENETICS; GRAFT VS HOST DISEASE; IMMUNOLOGY; METABOLISM; NEOPLASMS; PROCEDURES; T LYMPHOCYTE; TRANSLATIONAL RESEARCH;

ANIMALS; CELL- AND TISSUE-BASED THERAPY; GENE EXPRESSION; GENETIC THERAPY; GRAFT VS HOST DISEASE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84982132594     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2016.106     Document Type: Review

References (131)

1. Brown CE, Starr R, Aguilar B, Shami AF, Martinez C, D?Apuzzo M, et al. (2012). Stem-like tumor-initiating cells isolated from IL13R?2 expressing gliomas are targeted, and killed by IL13-zetakine-redirected T cells. Clin Cancer Res 18: 2199-2209.
2. Shaffer DR, Savoldo B, Yi, Z, Chow KK, Kakarla S, Spencer DM, et al. (2011). T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. Blood 117: 4304-4314.
3. Kumaresan PR, Manuri PR, Albert ND, Maiti S, Singh H, Mi, T, et al. (2014). Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. Proc Natl Acad Sci USA 111: 10660-10665.
4. Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C, et al. (2015). The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res 3: 125-135.
5. Hombach A, Hombach AA, and Abken H. (2010). Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc ?spacer? domain in the extracellular moiety of chimeric antigen receptors avoids ?off-Target? activation, and unintended initiation of an innate immune response. Gene Ther 17: 1206-1213.
6. Jonnalagadda M, Mardiros A, Urak R, Wang X, Hoffman LJ, Bernanke A, et al. (2015). Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding, and improve T cell persistence, and antitumor efficacy. Mol Ther 23: 757-768.
7. Hudecek M, Lupo-Stanghellini MT, Kosasih PL, Sommermeyer D, Jensen MC, Rader C, et al. (2013). Receptor affinity, and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res 19: 3153-3164.
8. James SE, Greenberg PD, Jensen MC, Lin Y, Wang J, Till BG, et al. (2008). Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J Immunol 180: 7028-7038.
9. Almåsbak H, Walseng E, Kristian A, Myhre MR, Suso EM, Munthe LA, et al. (2015). Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model. Gene Ther 22: 391-403.
10. Eshhar Z, Waks T, Gross G, and Schindler DG. (1993). Specific activation, and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains, and the gamma or zeta subunits of the immunoglobulin, and T-cell receptors. Proc Natl Acad Sci USA 90: 720-724.
11. Maher J, Brentjens RJ, Gunset G, Rivière I, and Sadelain M. (2002). Human T-lymphocyte cytotoxicity, and proliferation directed by a single chimeric TCRzeta /.CD28 receptor. Nat Biotechnol 20: 70-75.
12. Imai C, Mihara K, Andreansky M, Nicholson IC, Pui CH, Geiger TL, et al. (2004). Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 18: 676-684.
13. Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, et al. (2009). Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells, and increased antileukemic efficacy in vivo. Mol Ther 17: 1453-1464.
14. Pulè MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, and Brenner MK. (2005). A chimeric T cell antigen receptor that augments cytokine release, and supports clonal expansion of primary human T cells. Mol Ther 12: 933-941.
15. Song DG, Ye Q, Poussin M, Harms GM, Figini M, and Powell DJ Jr. (2012). CD27 costimulation augments the survival, and antitumor activity of redirected human T cells in vivo. Blood 119: 696-706.
16. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, et al. (2011). CD28costimulation improves expansion, and persistence of chimeric antigen receptormodified T cells in lymphoma patients. J Clin Invest 121: 1822-1826.
17. Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, et al. (2009). Control of large established tumor xenografts with genetically retargeted human T cells containing CD28, and CD137 domains. Proc Natl Acad Sci USA 106: 3360-3365.
18. Hoyos V, Savoldo B, Quintarelli C, Mahendravada A, Zhang M, Vera J, et al. (2010). Engineering CD19-specific T lymphocytes with interleukin-15, and a suicide gene to enhance their anti-lymphoma/leukemia effects, and safety. Leukemia 24: 1160-1170.
19. Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M, et al. (2012). Tumor-Targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119: 4133-4141.
20. Chinnasamy D, Yu, Z, Kerkar SP, Zhang L, Morgan RA, Restifo NP, et al. (2012). Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin Cancer Res 18: 1672-1683.
21. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. (2013). Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368: 1509-1518.
22. Porter DL, Levine BL, Kalos M, Bagg A, and June CH. (2011). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365: 725-733.
23. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. (2011). T cells with chimeric antigen receptors have potent antitumor effects, and can establish memory in patients with advanced leukemia. Sci Transl Med 3: 95ra73.
24. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. (2013). CD19-Targeted T cells rapidly induce molecular remissions in adults with chemotherapyrefractory acute lymphoblastic leukemia. Sci Transl Med 5: 177ra38.
25. Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, Stefanski J, et al. (2011). Safety, and persistence of adoptively transferred autologous CD19-Targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118: 4817-4828.
26. Cruz CR, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku, S, et al. (2013). Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 122: 2965-2973.
27. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. (2015). T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children, and young adults: a phase 1 dose-escalation trial. Lancet 385: 517-528.
28. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. (2014). Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371: 1507-1517.
29. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. (2014). Efficacy, and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6: 224ra25.
30. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, et al. (2015). Chemotherapy-refractory diffuse large B-cell lymphoma, and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 33: 540-549.
31. Kochenderfer JN, Yu Z, Frasheri D, Restifo NP, and Rosenberg SA. (2010). Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma, and normal B cells. Blood 116: 3875-3886.
32. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, et al. (2011). Antitumor activity, and long-Term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118: 6050-6056.
33. Batlevi CL, Matsuki E, Brentjens RJ, and Younes A. (2016). Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol 13: 25-40.
34. Sadelain M. (2015). CAR therapy: the CD19 paradigm. J Clin Invest 125: 3392-3400.
35. Maus MV, and June CH. (2016). Making better chimeric antigen receptors for adoptive T-cell therapy. Clin Cancer Res 22: 1875-1884.
36. Jackson HJ, Rafiq S, and Brentjens RJ. (2016). Driving CAR T-cells forward. Nat Rev Clin Oncol 13: 370-383.
37. van der Stegen SJ, Hamieh M, and Sadelain M. (2015). The pharmacology of secondgeneration chimeric antigen receptors. Nat Rev Drug Discov 14: 499-509.
38. June CH, Riddell SR, and Schumacher TN. (2015). Adoptive cellular therapy: a race to the finish line. Sci Transl Med 7: 280ps7.
39. Torikai H, Moyes J, and Cooper LN. (2014). Engineering T Cells to target tumor cells. In Cai W. (ed). Engineering in Translational Medicine. Springer: London pp 71-101.
40. Kloss CC, Condomines M, Cartellieri M, Bachmann M, and Sadelain M. (2013). Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 31: 71-75.
41. Fedorov VD, Themeli M, and Sadelain M. (2013). PD-1-, and CTLA-4-based inhibitory chimeric antigen receptors. (iCARs) divert off-Target immunotherapy responses. Sci Transl Med 5: 215ra172.
42. Inaguma Y, Akahori Y, Murayama Y, Shiraishi K, Tsuzuki-Iba S, Endoh A, et al. (2014). Construction, and molecular characterization of a T-cell receptor-like antibody, and CAR-T cells specific for minor histocompatibility antigen HA-1H. Gene Ther 21: 575-584.
43. Chames P, Willemsen RA, Rojas G, Dieckmann D, Rem L, Schuler G, et al. (2002). TCR-like human antibodies expressed on human CTLs mediate antibody affinitydependent cytolytic activity. J Immunol 169: 1110-1118.
44. Cooper LJN. (2015). Moving from tinkering in the garage to assembly line production: the manufacture of genetically modified T cells expressing chimeric antigen receptors. (CARs) comes on line. Cancer Gene Therapy 22: 64-66.
45. Heeger PS. (2003). T-cell allorecognition, and transplant rejection: a summary, and update. Am J Transplant 3: 525-533.
46. Felix NJ, and Allen PM. (2007). Specificity of T-cell alloreactivity. Nat Rev Immunol 7: 942-953.
47. Amrolia PJ, Muccioli-Casadei G, Huls H, Adams S, Durett A, Gee A, et al. (2006). Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood 108: 1797-1808.
48. Amrolia PJ, Muccioli-Casadei G, Yvon E, Huls H, Sili U, Wieder ED, et al. (2003). Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood 102: 2292-2299.
49. Solomon SR, Mielke S, Savani BN, Montero A, Wisch L, Childs R, et al. (2005). Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 106: 1123-1129.
50. Hartwig UF, Nonn M, Khan S, Meyer RG, Huber C, and Herr W. (2006). Depletion of alloreactive T cells via CD69: implications on antiviral antileukemic, and immunoregulatory T lymphocytes. Bone Marrow Transplant 37: 297-305.
51. Wehler TC, Nonn M, Brandt B, Britten CM, Gröne M, Todorova M, et al. (2007). Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic, and antitumor donor T-cell lines. Blood 109: 365-373.
52. Mielke S, Nunes R, Rezvani K, Fellowes VS, Venne A, Solomon SR, et al. (2008). A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched, and matched donor-recipient pairs using expanded T lymphocytes as antigenpresenting cells, and a TH9402-based photodepletion technique. Blood 111: 4392-4402.
53. Davies JK, Singh H, Huls H, Yuk D, Lee DA, Kebriaei P, et al. (2010). Combining CD19 redirection, and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies. Cancer Res 70: 3915-3924.
54. Anderson BE, McNiff J, Yan J, Doyle H, Mamula M, Shlomchik MJ, et al. (2003). Memory CD4+ T cells do not induce graft-versus-host disease. J Clin Invest 112: 101-108.
55. Foster AE, Marangolo M, Sartor MM, Alexander SI, Hu M, Bradstock KF, et al. (2004). Human CD62L- memory T cells are less responsive to alloantigen stimulation than CD62L+ naive T cells: potential for adoptive immunotherapy, and allodepletion. Blood 104: 2403-2409.
56. Arstila TP, Casrouge A, Baron V, Even J, Kanellopoulos J, and Kourilsky P. (1999). A direct estimate of the human alphabeta T cell receptor diversity. Science 286: 958-961.
57. Robins HS, Campregher PV, Srivastava SK, Wacher A, Turtle CJ, Kahsai O, et al. (2009). Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood 114: 4099-4107.
58. Chen BJ, Deoliveira D, Cui X, Le NT, Son J, Whitesides JF, et al. (2007). Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse. Blood 109: 3115-3123.
59. Bleakley M, Heimfeld S, Jones LA, Turtle C, Krause D, Riddell SR, et al. (2014). Engineering human peripheral blood stem cell grafts that are depleted of naïve T cells, and retain functional pathogen-specific memory T cells. Biol Blood Marrow Transplant 20: 705-716.
60. Gattinoni L, Klebanoff CA, and Restifo NP. (2012). Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer 12: 671-684.
61. Bleakley M, Heimfeld S, Loeb KR, Jones LA, Chaney C, Seropian S, et al. (2015). Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts. J Clin Invest 125: 2677-2689.
62. Haque T, Wilkie GM, Jones MM, Higgins CD, Urquhart G, Wingate P, et al. (2007). Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 110: 1123-1131.
63. Haque T, Wilkie GM, Taylor C, Amlot PL, Murad P, Iley A, et al. (2002). Treatment of Epstein-Barr-virus-positive post-Transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 360: 436-442.
64. Barker JN, Doubrovina E, Sauter C, Jaroscak JJ, Perales MA, Doubrovin M, et al. (2010). Successful treatment of EBV-Associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. Blood 116: 5045-5049.
65. Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, Antin JH, et al. (2013). Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 121: 5113-5123.
66. Amir AL, D?Orsogna LJ, Roelen DL, van Loenen MM, Hagedoorn RS, de Boer R, et al. (2010). Allo-HLA reactivity of virus-specific memory T cells is common. Blood 115: 3146-3157.
67. Melenhorst JJ, Leen AM, Bollard CM, Quigley MF, Price DA, Rooney CM, et al. (2010). Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood 116: 4700-4702.
68. Chien YH, and Konigshofer Y. (2007). Antigen recognition by gammadelta T cells. Immunol Rev 215: 46-58.
69. Xi, X, Guo Y, Chen H, Xu, C, Zhang H, Hu, H, et al. (2009). Antigen specificity of gammadelta T cells depends primarily on the flanking sequences of CDR3delta. J Biol Chem 284: 27449-27455.
70. Maeda Y, Reddy P, Lowler KP, Liu C, Bishop DK, and Ferrara JL. (2005). Critical role of host gammadelta T cells in experimental acute graft-versus-host disease. Blood 106: 749-755.
71. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Barrett TA, Bluestone JA, and Vallera DA. (1996). Lethal murine graft-versus-host disease induced by donor gamma/delta expressing T cells with specificity for host nonclassical major histocompatibility complex class Ib antigens. Blood 87: 827-837.
72. Drobyski WR, Vodanovic-Jankovic S, and Klein J. (2000). Adoptively transferred gamma delta T cells indirectly regulate murine graft-versus-host reactivity following donor leukocyte infusion therapy in mice. J Immunol 165: 1634-1640.
73. Vodanovic-Jankovic S, and Drobyski WR. (2006). Gammadelta T cells do not require fully functional cytotoxic pathways or the ability to recognize recipient alloantigens to prevent graft rejection. Biol Blood Marrow Transplant 12: 1125-1134.
74. Deniger DC, Maiti SN, Mi T, Switzer KC, Ramachandran V, Hurton LV, et al. (2014). Activating, and propagating polyclonal gamma delta T cells with broad specificity for malignancies. Clin Cancer Res 20: 5708-5719.
75. Deniger DC, Switzer K, Mi, T, Maiti S, Hurton L, Singh H, et al. (2013). Bispecific T-cells expressing polyclonal repertoire of endogenous T-cell receptors, and introduced CD19-specific chimeric antigen receptor. Mol Ther 21: 638-647.
76. Wilhelm M, Smetak M, Schaefer-Eckart K, Kimmel B, Birkmann J, Einsele H, et al. (2014). Successful adoptive transfer, and in vivo expansion of haploidentical T cells. J Transl Med 12: 45.
77. Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, and De Libero G. (2003). Human T cell receptor cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 197: 163-168.
78. Fisher JP, Heuijerjans J, Yan M, Gustafsson K, and Anderson J. (2014). T cells for cancer immunotherapy: a systematic review of clinical trials. Oncoimmunology 3: e27572.
79. Fisher JP, Flutter B, Wesemann F, Frosch J, Rossig C, Gustafsson K, et al. (2016). Effective combination treatment of GD2-expressing neuroblastoma, and Ewing?s sarcoma using anti-GD2 ch14.18/CHO antibody with V?9V?2+ T cells. Oncoimmunology 5: e1025194.
80. Pillai AB, George TI, Dutt S, Teo P, and Strober S. (2007). Host NKT cells can prevent graft-versus-host disease, and permit graft antitumor activity after bone marrow transplantation. J Immunol 178: 6242-6251.
81. Webb TJ, Bieler JG, Schneck JP, and Oelke M. (2009). Ex vivo induction, and expansion of natural killer T cells by CD1d1-Ig coated artificial antigen presenting cells. J Immunol Methods 346: 38-44.
82. Heczey A, Liu D, Tian G, Courtney AN, Wei J, Marinova E, et al. (2014). Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe, and effective cancer immunotherapy. Blood 124: 2824-2833.
83. Ljunggren HG, and Malmberg KJ. (2007). Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 7: 329-339.
84. Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T, et al. (2007). Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 110: 433-440.
85. Moretta L, Locatelli F, Pende D, Marcenaro E, Mingari MC, and Moretta A. (2011). Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood 117: 764-771.
86. Curti A, Ruggeri L, D?Addio A, Bontadini A, Dan E, Motta MR, et al. (2011). Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood 118: 3273-3279.
87. Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, et al. (2010). NKAML: a pilot study to determine the safety, and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 28: 955-959.
88. Bachanova V, Cooley S, Defor TE, Verneris MR, Zhang B, McKenna DH, et al. (2014). Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood 123: 3855-3863.
89. Imai C, Iwamoto S, and Campana D. (2005). Genetic modification of primary natural killer cells overcomes inhibitory signals, and induces specific killing of leukemic cells. Blood 106: 376-383.
90. Denman CJ, Senyukov VV, Somanchi SS, Phatarpekar PV, Kopp LM, Johnson JL, et al. (2012). Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One 7: e30264.
91. Shah NN, Baird K, Delbrook CP, Fleisher TA, Kohler ME, Rampertaap S, et al. (2015). Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation. Blood 125: 784-792.
92. Awong G, Herer E, Surh CD, Dick JE, La Motte-Mohs RN, and Zúñiga-Pflücker JC. (2009). Characterization in vitro, and engraftment potential in vivo of human progenitor T cells generated from hematopoietic stem cells. Blood 114: 972-982.
93. Mohtashami M, Shah DK, Nakase H, Kianizad K, Petrie HT, and Zúñiga-Pflücker JC. (2010). Direct comparison of Dll1-, and Dll4-mediated notch activation levels shows differential lymphomyeloid lineage commitment outcomes. J Immunol 185: 867-876.
94. Zakrzewski JL, Kochman AA, Lu SX, Terwey TH, Kim TD, Hubbard VM, et al. (2006). Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation. Nat Med 12: 1039-1047.
95. Zakrzewski JL, Suh D, Markley JC, Smith OM, King C, Goldberg GL, et al. (2008). Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors. Nat Biotechnol 26: 453-461.
96. De Oliveira SN, Ryan C, Giannoni F, Hardee CL, Tremcinska I, Katebian B, et al. (2013). Modification of hematopoietic stem/progenitor cells with CD19-specific chimeric antigen receptors as a novel approach for cancer immunotherapy. Hum Gene Ther 24: 824-839.
97. Gschweng E, De Oliveira S, and Kohn DB. (2014). Hematopoietic stem cells for cancer immunotherapy. Immunol Rev 257: 237-249.
98. Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, et al. (1997). HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versusleukemia. Science 276: 1719-1724.
99. Straathof KC, Pulè MA, Yotnda P, Dotti G, Vanin EF, Brenner MK, et al. (2005). An inducible caspase 9 safety switch for T-cell therapy. Blood 105: 4247-4254.
100. Bonini C, Bondanza A, Perna SK, Kaneko S, Traversari C, Ciceri F, et al. (2007). The suicide gene therapy challenge: how to improve a successful gene therapy approach. Mol Ther 15: 1248-1252.
101. Ciceri F, Bonini C, Stanghellini MT, Bondanza A, Traversari C, Salomoni M, et al. (2009). Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia. (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol 10: 489-500.
102. Berger C, Flowers ME, Warren EH, and Riddell SR. (2006). Analysis of transgenespecific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 107: 2294-2302.
103. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, et al. (2011). Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365: 1673-1683.
104. Zhou X, Di Stasi A, Tey SK, Krance RA, Martinez C, Leung KS, et al. (2014). Long-Term outcome after haploidentical stem cell transplant, and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood 123: 3895-3905.
105. Gargett T, and Brown MP. (2014). The inducible caspase-9 suicide gene system as a safety switch to limit on-Target off-Tumor toxicities of chimeric antigen receptor T cells. Front Pharmacol 5: 235.
106. Perez EE, Wang J, Miller JC, Jouvenot Y, Kim KA, Liu O, et al. (2008). Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 26: 808-816.
107. Miller JC, Tan S, Qiao G, Barlow KA, Wang J, Xia DF, et al. (2011). A TALE nuclease architecture for efficient genome editing. Nat Biotechnol 29: 143-148.
108. Zhang F, Cong L, Lodato S, Kosuri S, Church GM, and Arlotta P. (2011). Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. Nat Biotechnol 29: 149-153.
109. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. (2013). Multiplex genome engineering using CRISPR/Cas systems. Science 339: 819-823.
110. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, et al. (2013). RNA-guided human genome engineering via Cas9. Science 339: 823-826.
111. Torikai H, Reik A, Liu PQ, Zhou Y, Zhang L, Maiti S, et al. (2012). A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-Antigen-receptor, and eliminate expression of endogenous TCR. Blood 119: 5697-5705.
112. Osborn MJ, Webber BR, Knipping F, Lonetree CL, Tennis N, DeFeo AP, et al. (2016). Evaluation of TCR Gene Editing Achieved by TALENs CRISPR/Cas9, and megaTAL Nucleases. Mol Ther 24: 570-581.
113. Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, Hege KM, et al. (2012). Decade-long safety, and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 4: 132ra53.
114. Gattinoni L, Powell DJ Jr, Rosenberg SA, and Restifo NP. (2006). Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 6: 383-393.
115. Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, et al. (2005). Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 202: 907-912.
116. Poirot L, Philip B, Schiffer-Mannioui C, Le Clerre D, Chion-Sotinel I, Derniame S, et al. (2015). Multiplex genome-edited T-cell manufacturing platform for off-The-shelf adoptive T-cell immunotherapies. Cancer Res 75: 3853-3864.
117. Wrzesinski C, Paulos CM, Kaiser A, Muranski P, Palmer DC, Gattinoni L, et al. (2010). Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother 33: 1-7.
118. Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, et al. (2011). A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian, and breast cancer. Cytotherapy 13: 98-107.
119. Couzin-Frankel J. (2015). Baby?s leukemia recedes after novel cell therapy. Science 350: 731.
120. Martini S, Peters H, Böhler T, and Budde K. (2007). Current perspectives on FTY720. Expert Opin Investig Drugs 16: 505-518.
121. Marcus A, and Eshhar Z. (2011). Tumor-specific allogeneic cells for cancer therapy. Expert Opin Biol Ther 11: 1551-1554.
122. Hashimoto D, Asakura S, Matsuoka K, Sakoda Y, Koyama M, Aoyama K, et al. (2007). FTY720 enhances the activation-induced apoptosis of donor T cells, and modulates graft-versus-host disease. Eur J Immunol 37: 271-281.
123. Taylor PA, Kelly RM, Bade ND, Smith MJ, Stefanski HE, and Blazar BR. (2012). FTY720 markedly increases alloengraftment but does not eliminate host anti-donor T cells that cause graft rejection on its withdrawal. Biol Blood Marrow Transplant 18: 1341-1352.
124. Rong Z, Wang M, Hu, Z, Stradner M, Zhu S, Kong H, et al. (2014). An effective approach to prevent immune rejection of human ESC-derived allografts. Cell Stem Cell 14: 121-130.
125. Szot GL, Yadav M, Lang J, Kroon E, Kerr J, Kadoya K, et al. (2015). Tolerance induction, and reversal of diabetes in mice transplanted with human embryonic stem cell-derived pancreatic endoderm. Cell Stem Cell 16: 148-157.
126. Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitty R, et al. (2014). HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med 371: 339-348.
127. Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S, et al. (2011). A more efficient method to generate integration-free human iPS cells. Nat Methods 8: 409-412.
128. Taylor CJ, Peacock S, Chaudhry AN, Bradley JA, and Bolton EM. (2012). Generating an iPSC bank for HLA-matched tissue transplantation based on known donor, and recipient HLA types. Cell Stem Cell 11: 147-152.
129. Torikai H, Reik A, Soldner F, Warren EH, Yuen C, Zhou Y, et al. (2013). Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood 122: 1341-1349.
130. Jandus C, Boligan KF, Chijioke O, Liu H, Dahlhaus M, Démoulins T, et al. (2014). Interactions between Siglec-7/9 receptors, and ligands influence NK cell-dependent tumor immunosurveillance. J Clin Invest 124: 1810-1820.
131. Torikai H, Mi, T, Gragert L, Maiers M, Najjar A, Ang S, et al. (2016). Genetic editing of HLA expression in hematopoietic stem cells to broaden their human application. Sci Rep 6: 21757.